CD56和CD64高表达对成人AML1/ETO+白血病患者长期生存的影响  

Long-term survival analysis of AML1/ETO positive leukemia patients with expression of CD56 and CD64

作　　者：孟伟[1] 梁梦妮 魏永强[3] 余国攀[3] 阴常新 蒋玲[3] MENG Wei LIANG Meng - ni WEI Yong - qiang YU Guo - pan YIN Chang - xin JIANG Ling(Department of Bio- chemistry, College of basic medicine science, Southern medical university, Guangzhou 510515, Guangdong, China)

机构地区：[1]南方医科大学生物化学与分子生物学教研室,广东广州510515 [2]南方医科大学第一临床医学院,广东广州510515 [3]南方医科大学南方医院血液内科,广东广州510515

出　　处：《广东医学》2017年第18期2773-2777,共5页Guangdong Medical Journal

基　　金：国家自然科学基金资助项目(编号:81400103);广东省自然科学基金资助项目(编号:2014A030310061)

摘　　要：目的探讨CD56和CD64对成人AML1/ETO+急性髓系白血病患者长期生存的影响。方法回顾性分析35例成人AML1/ETO+急性髓系白血病患者的临床资料,应用Log-Rank检验和Cox回归模型对患者的性别、年龄、初诊时白细胞计数、免疫表型、首疗程是否完全缓解、c-kit基因突变、复杂核型、髓外白血病进行单因素和多因素综合分析。结果 35例患者随访3~87个月,中位随访时间33个月,单因素分析显示年龄、性别、髓外白血病、复杂核型、首疗程是否完全缓解、CD19、CD9对患者3年和5年总体生存率无显著影响(P>0.05),初诊时白细胞计数、CD56^+、CD64^+的表达对AML1/ETO+的长期生存具有显著性差异(P=0.045,P=0.044,P=0.045)。多因素分析显示,CD56表达是影响AML1/ETO+急性髓系白血病患者长期生存重要的独立预后因素。其中CD56^+CD64+显著影响患者长期生存(P=0.012)。结论 CD56是AML1/ETO+急性髓系白血病患者独立的预后不良因素,且CD56+、CD64+双表达预后最差。Objective To investigate the effects of CD56 and CD64 on long - term survival in patients with AML/ ETO - positive acute myeloid leukemia. Methods An institutional retrospective study was performed on 35 AML/ETO - positive acute myeloid leukemia patients from May 2010 to August 2016. Univarlate and multifactorial analysis of potential factors influencing survival, including gender, age, initial WBC count, immunophenotype, chemotherapy course to com- plete remission （CR） , c -kit gene mutation, complex karyotype and extramedullary leukemia, were carried out by using Log - rank test and Cox regression model. Results Thirty - five patients were followed up for 3 to 87 months （ median 33 months）. Univariate analysis showed that age, sex, extramedullary leukemia, complex karyotype, chemotherapy course to CR, CD19 or CD9 didn＇t significanhy affect long- term survival, while initial WBC count, CD56 and CD64 were critical factors on it （P = 0. 045, P= 0. 044, P = 0. 045）. Multivariate analysis showed that CD56 expression was an independent prognostic factor for AML/ETO positive patients with acute myeloid leukemia. Patients with both CD56 positive and CI）64 positive got the least long - term survival rate （P = 0. 012）. Conclusion CD56 is an independent prognostic factor for AML/ETO- positive acute myeloid leukemia patients, and CD56 and CD64 double -expression have the poorest prognosis.

关 键 词：CD56 CD64 AML1/ETO+ 急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]